- |||||||||| imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Clinical, Review, Journal: A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date. (Pubmed Central) - Dec 5, 2020 The most common adverse drug events associated with I-R were nausea (6%), diarrhea (6%), and headache (4%). I-R is a new beta-lactam/beta-lactamase inhibitor combination that will be most likely used for patients with multidrug-resistant gram-negative infections in which there are limited or no available alternative treatment options.
- |||||||||| imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Journal: Activity of imipenem/relebactam against carbapenemase-producing Enterobacteriaceae with high colistin resistance. (Pubmed Central) - Sep 19, 2020 Imipenem-relebactam may provide a valuable therapeutic option for the treatment of ICU patients with LRTI caused by Gram-negative bacilli resistant to commonly used β-lactams, as it demonstrated potent in vitro activity against the majority of tested β-lactam-nonsusceptible and MDR Gram-negative bacilli from ICU patients with LRTIs in United States hospitals. Imipenem/relebactam was the most potent agent tested against CPE in this study and may be a useful addition to the antimicrobial armamentarium to treat infections caused by these pathogens.
- |||||||||| imipenem/relebactam / Merck (MSD)
[VIRTUAL] In Vitro Activity of Imipenem/Relebactam against Gram-Negative Pathogens from Patients with Bloodstream Infections in the United States and Canada – SMART 2018 () - Aug 14, 2020 - Abstract #IDWeek2020IDWEEK_749; Multidrug-resistance (MDR) was defined as resistance to ≥3 of the following sentinel drugs: amikacin, aztreonam, cefepime, ceftazidime (NME only), ciprofloxacin, colistin, imipenem, and piperacillin/tazobactam...Susceptibility to IMI/REL and comparators of selected species and subsets of resistant phenotypes is shown in the table.IMI/REL was active against 99.8% of NME isolates; only meropenem, ceftazidime/avibactam, and amikacin showed comparable activity... In the US and Canada, IMI/REL could provide an important treatment option for patients with BSI caused by resistant gram-negative organisms.
- |||||||||| imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Journal: Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17. (Pubmed Central) - Aug 13, 2020 IMI/REL provides a potential treatment option for ICU patients in Asia/Pacific with infections caused by KP and PA. Relebactam restored in vitro susceptibility to imipenem for most imipenem-non-susceptible and MDR clinical isolates of P. aeruginosa from European patients.
- |||||||||| relebactam (MK-7655) / Merck (MSD)
Journal: Imipenem/cilastatin sodium/relebactam fixed combination to treat urinary infections and complicated intra-abdominal bacterial infections. (Pubmed Central) - Jul 30, 2020 The combination (Recarbrio) has been designated as a qualified infectious disease product (QIDP) and obtained FDA approval in 2019 for the treatment of cUTI and cIAI caused by susceptible Gram-negative microorganisms in adult patients with limited or no alternative treatment options. The product was also approved by the European Medicines Agency (EMA) in 2020 for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
- |||||||||| imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD)
Clinical, PK/PD data, Journal: Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial Infections. (Pubmed Central) - Jul 29, 2020 Simulations were used to calculate probability of joint target attainment (ratio of free drug area under the curve from 0-24 hours to minimum inhibitory concentration [fAUC/MIC] for relebactam and percentage of time the free drug concentration exceeded the MIC [%fT>MIC] for imipenem) for the proposed imipenem/relebactam dose of 500/250 mg, with adjustments for patients with renal impairment, administered as a 30-minute intravenous infusion four times daily. These dosing regimens provide sufficient antibacterial coverage (MIC≤4 μg/mL) for all renal groups.
- |||||||||| imipenem/relebactam / Merck (MSD), relebactam (MK-7655) / Merck (MSD), amoxicillin / Generic mfg.
Journal, Combination therapy: Effect of Amoxicillin in combination with Imipenem-Relebactam against Mycobacterium abscessus. (Pubmed Central) - May 28, 2020 Furthermore, we reverse the susceptibility by overexpressing Bla in M. abscessus, demonstrating relebactam-Bla target engagement. Finally, we highlight the in vitro efficacy of this combination against a panel of M. abscessus clinical isolates, revealing the therapeutic potential of the amoxicillin-imipenem-relebactam combination.
|